RANOLAZINE | RANOLAZINE | ATC C01EB18
ANTIANGINAL CARDIOVASCULAR ANTIANGINAL TREATMENT OF CHRONIC ANGINA INHIBIT THE CARDIAC LATE SODIUM CURRENT VOLTAGE-GATED NA(+) CHANNELS (NAV) INHIBITOR ALPHA1-ADRENERGIC RECEPTOR ANTAGONIST (PMID26655634) | ORAL | Cmax 6.08 MICROMOLAR Tmax 3.5 HOUR F 76 PERCENT PPB 62 PERCENT HT 7 HOUR SOLUBILITY VERY SLIGHTLY SOLUBLE IN WATER | VOLTAGE-GATED NA(+) CHANNELS (NAV) (PMID26655634) ALPHA1-ADRENERGIC RECEPTOR (PMID26655634) | Sodium channel protein type 5 subunit alpha UNIPROT Q14524 SCN5A more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |